Hydroxyl Radical Protein Footprinting: A Mass Spectrometry-Based Structural Method for Studying the Higher Order Structure of Proteins
Hydroxyl radical protein footprinting (HRPF) coupled to mass spectrometry has been efficiently used to analyze a plethora of protein-related questions. The tactic, which makes use of hydroxyl radicals to oxidatively modify solvent-accessible amino acids, can inform on protein interplay websites and areas of conformational change.
Hydroxyl radical-based footprinting was initially developed to review nucleic acids, however coupling the tactic with mass spectrometry has enabled the research of proteins. The tactic has undergone a number of developments since its inception which have elevated its utility for extra diversified purposes corresponding to protein folding and the research of biotherapeutics.
As well as, current improvements have led to the research of more and more complicated techniques together with cell lysates and intact cells. Technological advances have additionally elevated throughput and allowed for higher management of experimental situations. On this assessment, we offer a short historical past of the sector of HRPF and element current improvements and purposes within the area.
Missense mutations involvement in COX-2 construction, and protein-substrate binding affinity: in-silico research
Cyclooxygenase-2 (COX-2) is an inducible inflammatory enzyme, which produces prostanoids from arachidonic acid. COX-2 overexpression and over-activity may cause irritation, tumorigenesis, and angiogenesis. Prostanoids are the primary motive for the irritation, and enhance of mitogenesis by COX-2.
So, any change corresponding to mutations that may result in COX-2 over-activity may ignite the tumor conditions with enhance of prostanoids manufacturing is considered one of its methods. The goal of this research was to test the impact of 166 missense mutations of COX-2 on protein options that may have an effect on the COX-2 exercise corresponding to protein stability, fluctuation, 2D construction, and its binding affinity with the substrate by in silico strategies, community modeling, and docking calculations, by which 44 of them proven to be deleterious.
Amongst them, the S124I and S474F mutations can enhance the soundness of the protein. 11.36% of deleterious nsSNPs have been a part of the substrate-binding area amongst which the M508T, H337R, and V511G have the potential to have an effect on the protein by 2D construction alteration.
V511G can enhance binding affinity and H337R confirmed a small lower within the deformation total vitality that may symbolize a lower within the stability of COX-2. Additionally, L517S confirmed a major lower within the binding energy of COX-2/substrate however primarily based on the anisotropic community modeling this mutation has a twin impact on COX-2 stability. These nsSNPs/mutations have the potential inflicting a rise or lower of tumorigenesis as a result of rising of COX-2 stability and its binding affinity can result in altering its exercise.
Cryo-EM construction willpower of small proteins by nanobody-binding scaffolds (Legobodies)
We describe a common methodology that permits construction willpower of small proteins by single-particle cryo-electron microscopy (cryo-EM). The tactic relies on the supply of a target-binding nanobody, which is then rigidly connected to 2 scaffolds: 1) a Fab fragment of an antibody directed in opposition to the nanobody and a pair of) a nanobody-binding protein A fraction fused to maltose binding protein and Fab-binding domains.
The general ensemble of ∼120 kDa, referred to as Legobody, doesn’t perturb the nanobody-target interplay, is well recognizable in EM pictures because of its distinctive form, and facilitates particle alignment in cryo-EM picture processing.
The utility of the tactic is demonstrated for the KDEL receptor, a 23-kDa membrane protein, leading to a map at 3.2-Å total decision with density enough for de novo mannequin constructing, and for the 22-kDa receptor-binding area (RBD) of SARS-CoV-2 spike protein, leading to a map at 3.6-Å decision that permits evaluation of the binding interface to the nanobody. The Legobody strategy thus overcomes the present dimension limitations of cryo-EM evaluation.
Human Surfactant Protein SP-A1 and SP-A2 Variants Differentially Have an effect on the Alveolar Microenvironment, Surfactant Construction, Regulation and Perform of the Alveolar Macrophage, and Animal and Human Survival Underneath Numerous Circumstances
The human innate host protection molecules, SP-A1 and SP-A2 variants, differentially have an effect on survival after an infection in mice and in lung transplant sufferers. SP-A interacts with the sentinel innate immune cell within the alveolus, the alveolar macrophage (AM), and modulates its perform and regulation.
SP-A additionally performs a task in pulmonary surfactant-related points, together with surfactant construction and reorganization. For many (if not all) pulmonary illnesses there’s a dysregulation of host protection and inflammatory processes and/or surfactant dysfunction or deficiency. As a result of SP-A performs a task in each of those common processes the place one or each might turn out to be aberrant in pulmonary illness, SP-A stands to be an essential molecule in well being and illness.
In people (in contrast to in rodents) SP-A is encoded by two genes (SFTPA1 and SFTPA2) and every has been recognized with in depth genetic and epigenetic complexity. On this assessment, we deal with practical, structural, and regulatory variations between the 2 SP-A gene-specific merchandise, SP-A1 and SP-A2, and amongst their corresponding variants.
We focus on the differential impression of those variants on the surfactant construction, the alveolar microenvironment, the regulation of epithelial kind II miRNome, the regulation and performance of the AM, the general survival of the organism after an infection, and others. Though there have been numerous critiques on SP-A, that is the primary assessment that gives such a complete account of the variations between human SP-A1 and SP-A2.
Advanced construction of the acyltransferase VinK and the service protein VinL with a pantetheine cross-linking probe
Acyltransferases are answerable for the choice and loading of acyl items onto service proteins in polyketide and fatty-acid biosynthesis. Regardless of the significance of protein-protein interactions between the acyltransferase and the service protein, structural info on acyltransferase-carrier protein interactions is proscribed due to the transient interactions between them.
Within the biosynthesis of the polyketide vicenistatin, the acyltransferase VinK acknowledges the service protein VinL for the switch of a dipeptidyl unit. The crystal construction of a VinK-VinL covalent complicated fashioned with a 1,2-bismaleimidoethane cross-linking reagent has been decided beforehand.
Right here, the crystal construction of a VinK-VinL covalent complicated fashioned with a pantetheine cross-linking probe is reported at 1.95 Å decision. Within the construction of the VinK-VinL-probe complicated, the pantetheine probe that’s connected to VinL is covalently linked to the aspect chain of the mutated Cys106 of VinK.
SARS-CoV Spike (Middle) |
|||
| GWB-7B5EA5 | GenWay Biotech | 1 mg | Ask for price |
SARS-CoV Spike Protein |
|||
| abx060655-100g | Abbexa | 100 µg | Ask for price |
SARS-CoV Spike Protein |
|||
| abx060655-10g | Abbexa | 10 µg | EUR 1962.5 |
SARS-CoV Spike Protein |
|||
| abx060655-1mg | Abbexa | 1 mg | EUR 2030.4 |
SARS-CoV Spike Protein |
|||
| abx060655-50g | Abbexa | 50 µg | Ask for price |
SARS-CoV Spike Protein |
|||
| abx060656-100g | Abbexa | 100 µg | Ask for price |
SARS-CoV Spike Protein |
|||
| abx060656-10g | Abbexa | 10 µg | EUR 1962.5 |
SARS-CoV Spike Protein |
|||
| abx060656-50g | Abbexa | 50 µg | Ask for price |
SARS-CoV Spike Protein |
|||
| abx060657-100g | Abbexa | 100 µg | Ask for price |
SARS-CoV Spike Protein |
|||
| abx060657-10g | Abbexa | 10 µg | EUR 1962.5 |
SARS-CoV Spike Protein |
|||
| abx060657-50g | Abbexa | 50 µg | Ask for price |
SARS-CoV Spike Antibody |
|||
| 3219-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3219-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3221-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3221-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3223-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3223-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3225-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 3225-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: SARS-CoV Spike antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
|||
SARS-CoV Spike Antibody |
|||
| 21807 | SAB | 100ul | EUR 1039 |
SARS-CoV Spike Antibody |
|||
| 21808 | SAB | 100ul | EUR 1039 |
SARS-CoV Spike Antibody |
|||
| 21809 | SAB | 100ul | EUR 1039 |
SARS-CoV Spike Antibody |
|||
| 21810 | SAB | 100ul | EUR 1039 |
SARS-CoV Spike Antibody |
|||
| 21811 | SAB | 100ul | EUR 1039 |
SARS-CoV Spike Antibody |
|||
| 21812 | SAB | 100ul | EUR 1039 |
SARS-CoV Spike Antibody |
|||
| MBS9457577-005mL | MyBiosource | 0.05mL | EUR 530 |
SARS-CoV Spike Antibody |
|||
| MBS9457577-01mL | MyBiosource | 0.1mL | EUR 825 |
SARS-CoV Spike Antibody |
|||
| MBS9457577-5x01mL | MyBiosource | 5x0.1mL | EUR 3560 |
SARS-CoV Spike Antibody |
|||
| MBS9457578-005mL | MyBiosource | 0.05mL | EUR 530 |
SARS-CoV Spike Antibody |
|||
| MBS9457578-01mL | MyBiosource | 0.1mL | EUR 825 |
SARS-CoV Spike Antibody |
|||
| MBS9457578-5x01mL | MyBiosource | 5x0.1mL | EUR 3560 |
SARS-CoV Spike Antibody |
|||
| MBS9457579-005mL | MyBiosource | 0.05mL | EUR 530 |
SARS-CoV Spike Antibody |
|||
| MBS9457579-01mL | MyBiosource | 0.1mL | EUR 825 |
SARS-CoV Spike Antibody |
|||
| MBS9457579-5x01mL | MyBiosource | 5x0.1mL | EUR 3560 |
SARS-CoV Spike Antibody |
|||
| MBS9457580-005mL | MyBiosource | 0.05mL | EUR 530 |
SARS-CoV Spike Antibody |
|||
| MBS9457580-01mL | MyBiosource | 0.1mL | EUR 825 |
SARS-CoV Spike Antibody |
|||
| MBS9457580-5x01mL | MyBiosource | 5x0.1mL | EUR 3560 |
SARS-CoV Spike Antibody |
|||
| MBS9457581-005mL | MyBiosource | 0.05mL | EUR 530 |
SARS-CoV Spike Antibody |
|||
| MBS9457581-01mL | MyBiosource | 0.1mL | EUR 825 |
SARS-CoV Spike Antibody |
|||
| MBS9457581-5x01mL | MyBiosource | 5x0.1mL | EUR 3560 |
SARS-CoV Spike Antibody |
|||
| MBS9457582-005mL | MyBiosource | 0.05mL | EUR 530 |
SARS-CoV Spike Antibody |
|||
| MBS9457582-01mL | MyBiosource | 0.1mL | EUR 825 |
SARS-CoV Spike Antibody |
|||
| MBS9457582-5x01mL | MyBiosource | 5x0.1mL | EUR 3560 |
SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] 100 ul |
|||
| BSV-COV-AB-02 | BioServUK | 100 ul | EUR 602 |
|
Description: SARS-CoV/ SARS-CoV-2 (COVID-19) spike antibody [1A9] (Spike (S2), Monoclonal) |
|||
SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody |
|||
| abx137719-100tests | Abbexa | 100 tests | EUR 1237.5 |
SARS CoV-2 IgG Spike S1 (CoV-2 IgG S1) Antibody |
|||
| abx137720-100tests | Abbexa | 100 tests | EUR 1237.5 |
SARS CoV-2 IgM Spike S1 (CoV-2 IgM S1) Antibody |
|||
| abx137721-100tests | Abbexa | 100 tests | EUR 225 |
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
| 3525-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
| 3525-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) spike antibody |
|||
| BSV-COV-AB-05 | BioServUK | 25 ul | EUR 286 |
|
Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal) |
|||
SARS-CoV-2 (COVID-19) spike antibody |
|||
| BSV-COV-AB-06 | BioServUK | 100 ul | EUR 557 |
|
Description: SARS-CoV-2 (COVID-19) spike antibody (Spike (S1), Polyclonal) |
|||
SARS-CoV-2 (COVID-19) Spike 681P Antibody |
|||
| 9091-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike 681P Antibody |
|||
| 9091-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS CoV 2 Spike Protein (RBD), His tag, E.coli |
|||
| E2S209916P | EnoGene | 100ul | EUR 595 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
SARS-CoV Spike (C-term) |
|||
| GWB-FCD9A4 | GenWay Biotech | 1 mg | Ask for price |
SARS-CoV Spike (N-term) |
|||
| GWB-51A5A4 | GenWay Biotech | 1 mg | Ask for price |
SARS-CoV-2 Spike Peptide |
|||
| 9083P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: (NT) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
| 9087P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: (CT) SARS-CoV-2 Spike RBD peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
| 9091P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike Peptide |
|||
| 9095P | ProSci | 0.05 mg | EUR 235.5 |
|
Description: (IN) SARS-CoV-2 Spike peptide |
|||
SARS-CoV-2 Spike Protein |
|||
| abx655879-100g | Abbexa | 100 µg | EUR 337.5 |
SARS-CoV-2 Spike Protein |
|||
| abx655880-100g | Abbexa | 100 µg | EUR 337.5 |
SARS-CoV-2 Spike Protein |
|||
| abx655881-100g | Abbexa | 100 µg | EUR 337.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620083-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Peptide |
|||
| abx620083-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620083-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Peptide |
|||
| abx620084-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Peptide |
|||
| abx620084-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620084-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Peptide |
|||
| abx620085-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Peptide |
|||
| abx620085-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620085-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Peptide |
|||
| abx620086-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Peptide |
|||
| abx620086-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620086-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Peptide |
|||
| abx620087-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Peptide |
|||
| abx620087-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620087-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Peptide |
|||
| abx620088-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Peptide |
|||
| abx620088-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620088-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Peptide |
|||
| abx620089-100g | Abbexa | 100 µg | EUR 250 |
SARS-CoV-2 Spike Peptide |
|||
| abx620089-1mg | Abbexa | 1 mg | EUR 1362.5 |
SARS-CoV-2 Spike Peptide |
|||
| abx620089-200g | Abbexa | 200 µg | EUR 350 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154644-005mg | MyBiosource | 0.05mg | EUR 205 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154644-5x005mg | MyBiosource | 5x0.05mg | EUR 900 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154645-005mg | MyBiosource | 0.05mg | EUR 205 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154645-5x005mg | MyBiosource | 5x0.05mg | EUR 900 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154646-005mg | MyBiosource | 0.05mg | EUR 205 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154646-5x005mg | MyBiosource | 5x0.05mg | EUR 900 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154655-005mg | MyBiosource | 0.05mg | EUR 205 |
SARS-CoV-2 Spike Peptide |
|||
| MBS154655-5x005mg | MyBiosource | 5x0.05mg | EUR 900 |
SARS-CoV Spike Rabbit pAb |
|||
| A20605 | Abclonal | 20μL | EUR 88.56 |
SARS-CoV Spike Rabbit pAb |
|||
| E45R29003N | EnoGene | 50 ul | EUR 297.75 |
SARS-CoV Spike Rabbit pAb |
|||
| MBS9144354-002mL | MyBiosource | 0.02mL | EUR 200 |
SARS-CoV Spike Rabbit pAb |
|||
| MBS9144354-005mL | MyBiosource | 0.05mL | EUR 255 |
SARS-CoV Spike Rabbit pAb |
|||
| MBS9144354-01mL | MyBiosource | 0.1mL | EUR 345 |
SARS-CoV Spike Rabbit pAb |
|||
| MBS9144354-02mL | MyBiosource | 0.2mL | EUR 545 |
SARS-CoV Spike Rabbit pAb |
|||
| MBS9144354-5x02mL | MyBiosource | 5x0.2mL | EUR 2265 |
SARS-CoV-2 Spike Antibody |
|||
| 10-2868 | Fitzgerald | 1 mg | EUR 1000 |
|
Description: SARS-CoV-2 Spike Antibody, Recombinant Human |
|||
SARS-CoV-2 Spike Antibody |
|||
| 10-2869 | Fitzgerald | 1 mg | EUR 1000 |
|
Description: SARS-CoV-2 Spike Antibody, Recombinant Human |
|||
SARS-CoV-2 Spike Antibody |
|||
| 10-2870 | Fitzgerald | 1 mg | EUR 1000 |
|
Description: SARS-CoV-2 Spike Antibody, Recombinant Human |
|||
SARS-CoV-2 Spike Antibody |
|||
| 10-2871 | Fitzgerald | 1 mg | EUR 1000 |
|
Description: SARS-CoV-2 Spike Antibody, Recombinant Human |
|||
SARS-CoV-2 Spike Antibody |
|||
| 10-2906 | Fitzgerald | 1 mg | EUR 225 |
|
Description: Anti-SARS-CoV-2 Spike Protein Monoclonal antibody |
|||
SARS-CoV-2 Spike Antibody |
|||
| 10-2907 | Fitzgerald | 1 mg | EUR 225 |
|
Description: Anti-SARS-CoV-2 Spike Protein Monoclonal antibody |
|||
SARS-CoV-2 Spike Antibody |
|||
| abx229971-100g | Abbexa | 100 µg | EUR 325 |
SARS-COV-2 Spike Antibody |
|||
| E40M732 | EnoGene | N/A | EUR 346.5 |
|
Description: N/A |
|||
SARS-CoV-2 Spike Antibody |
|||
| MBS5316661-1mg | MyBiosource | 1mg | EUR 335 |
SARS-CoV-2 Spike Antibody |
|||
| MBS5316661-5x1mg | MyBiosource | 5x1mg | EUR 1350 |
SARS-CoV-2 Spike Antibody |
|||
| MBS5316705-1mg | MyBiosource | 1mg | EUR 335 |
SARS-CoV-2 Spike Antibody |
|||
| MBS5316705-5x1mg | MyBiosource | 5x1mg | EUR 1350 |
SARS-CoV-2 Spike, antibody |
|||
| MBS664123-05mg | MyBiosource | 0.5mg | EUR 420 |
SARS-CoV-2 Spike, antibody |
|||
| MBS664123-10mg | MyBiosource | 10mg | EUR 3605 |
SARS-CoV-2 Spike, antibody |
|||
| MBS664123-15mg | MyBiosource | 15mg | EUR 5095 |
SARS-CoV-2 Spike, antibody |
|||
| MBS664123-1mg | MyBiosource | 1mg | EUR 540 |
SARS-CoV-2 Spike, antibody |
|||
| MBS664123-5mg | MyBiosource | 5mg | EUR 1960 |
SARS-CoV/SARS-CoV-2 Spike Antibody,Chimeric MAb |
|||
| E27D2019-A5 | EnoGene | 2019-nCoV-Chimeric-monoclonal-antibody | EUR 416.5 |
|
Description: 2019-nCoV Chimeric monoclonal antibody |
|||
SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb |
|||
| E27D2019-A6 | EnoGene | 2019-nCoV-Chimeric-monoclonal-antibody | EUR 416.5 |
|
Description: 2019-nCoV Chimeric monoclonal antibody |
|||
SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb |
|||
| MBS8110617-002mL | MyBiosource | 0.02mL | EUR 210 |
SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb |
|||
| MBS8110617-01mL | MyBiosource | 0.1mL | EUR 480 |
SARS-CoV/SARS-CoV-2 Spike antibody, Chimeric MAb |
|||
| MBS8110617-5x01mL | MyBiosource | 5x0.1mL | EUR 2010 |
SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb |
|||
| MBS8119476-002mL | MyBiosource | 0.02mL | EUR 210 |
SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb |
|||
| MBS8119476-01mL | MyBiosource | 0.1mL | EUR 480 |
SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb |
|||
| MBS8119476-5x01mL | MyBiosource | 5x0.1mL | EUR 2010 |
SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb |
|||
| MBS8119477-002mL | MyBiosource | 0.02mL | EUR 210 |
SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb |
|||
| MBS8119477-01mL | MyBiosource | 0.1mL | EUR 480 |
SARS-CoV/SARS-CoV-2 Spike antibody,Chimeric MAb |
|||
| MBS8119477-5x01mL | MyBiosource | 5x0.1mL | EUR 2010 |
SARS-CoV/SARS-CoV-2 Spike Antibody,Chimeric MAb |
|||
| MBS8119480-002mL | MyBiosource | 0.02mL | EUR 210 |
SARS-CoV/SARS-CoV-2 Spike Antibody,Chimeric MAb |
|||
| MBS8119480-01mL | MyBiosource | 0.1mL | EUR 480 |
SARS-CoV/SARS-CoV-2 Spike Antibody,Chimeric MAb |
|||
| MBS8119480-5x01mL | MyBiosource | 5x0.1mL | EUR 2010 |
The interplay interface between VinK and VinL is actually the identical within the two VinK-VinL complicated buildings, though the place of the pantetheine linker barely differs. This structural statement means that interface interactions usually are not affected by the cross-linking technique used.
